ABSTRACT
AIMS: To assess whether assimilation tests in isolation remain a valid method of identification of yeasts, when applied to a wide range of environmental and spoilage isolates. METHODS AND RESULTS: Seventy-one yeast strains were isolated from a soft drinks factory. These were identified using assimilation tests and by D1/D2 rDNA sequencing. When compared to sequencing, assimilation test identifications (MicroLog™) were 18·3% correct, a further 14·1% correct within the genus and 67·6% were incorrectly identified. The majority of the latter could be attributed to the rise in newly reported yeast species. CONCLUSIONS: Assimilation tests alone are unreliable as a universal means of yeast identification, because of numerous new species, variability of strains and increasing coincidence of assimilation profiles. Assimilation tests still have a useful role in the identification of common species, such as the majority of clinical isolates. SIGNIFICANCE AND IMPACT OF THE STUDY: It is probable, based on these results, that many yeast identifications reported in older literature are incorrect. This emphasizes the crucial need for accurate identification in present and future publications.
Subject(s)
Yeasts/genetics , Beverages/microbiology , DNA, Fungal , DNA, Ribosomal/genetics , Food Microbiology/methods , Food Microbiology/standards , Humans , Mycological Typing Techniques/methods , Mycological Typing Techniques/standards , Saccharomyces cerevisiae/classification , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/isolation & purification , Yeasts/classification , Yeasts/isolation & purificationABSTRACT
BACKGROUND: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when given as combination therapy. METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin. RESULTS: Combretastatin A4 phosphate was escalated from 36 to 54 mg m(-2) with the carboplatin area under the concentration curve (AUC) 4-5, from 27 to 54 mg m(-2) with paclitaxel 135-175 mg m(-2), and from 54 to 72 mg m(-2) with carboplatin AUC 5 and paclitaxel 175 mg m(-2). Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients. Grade 1-3 hypertension (26% of patients) and grade 1-3 tumour pain (65% of patients) were the most typical non-haematological toxicities. Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72 mg m(-2). Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma. CONCLUSION: The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate premedication and had antitumour activity in patients who were heavily pretreated.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/therapeutic use , Neoplasms/drug therapy , Paclitaxel/therapeutic use , Stilbenes/therapeutic use , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/toxicity , Ataxia/chemically induced , Carboplatin/toxicity , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/pathology , Dose-Response Relationship, Drug , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/pathology , Female , Humans , Infusions, Intravenous , Life Expectancy , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Neoplasms/pathology , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Paclitaxel/toxicity , Patient Selection , Stilbenes/administration & dosage , Stilbenes/toxicityABSTRACT
BACKGROUND: Oral hypoglycemic agents (OHAs) are an important component in the management of type 2 diabetes mellitus (DM). Large-scale studies have demonstrated that tight glycemic control with such agents can reduce the frequency and severity of long-term DM-related complications. OBJECTIVES: The main goal of this study was to examine the impact of depression on utilization patterns of OHAs in patients newly diagnosed with type 2 DM. A secondary objective was to estimate the impact of depression on discontinuation and modification of pharmacotherapy for DM in these patients. METHODS: Patients newly diagnosed with type 2 DM during a 3-year period (1998-2000) were identified from a Medicaid claims database. Presence of preexisting depression was determined on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. The patient cohort was followed up until they received their first prescription for an OHA (1998-2001); this date was treated as the index date for the study. Utilization patterns (ie, discontinuation, augmentation, switching, non-modification) for OHAs were computed for a 12-month follow-up period after the index date. A multivariate framework was used to estimate the impact of depression on utilization patterns, controlling for confounders such as demographics, comorbidity, provider interaction, drug regimen complexity, and DM severity. RESULTS: A total of 1237 newly diagnosed type 2 DM patients were identified (depressed, n=446; nondepressed, n=791). A higher number of depressed patients (23.32%) switched or augmented therapy compared with nondepressed patients (16.18%). Also, a higher fraction of depressed patients (39.46%) discontinued OHA therapy compared with nondepressed patients (32.87%). Results of a multinomial logistic regression indicated that, controlling for covariates, patients with depression were 1.72 times more likely to switch (P=0.046) and 1.89 times more likely to augment therapy (P=0.004) compared with nondepressed patients. Logistic regression analysis also indicated that, controlling for confounding covariates, patients with depression were 1.72 times more likely to modify initial OHA therapy compared with patients without depression (P=0.003). CONCLUSION: Depression was significantly associated with utilization patterns of OHAs in these patients newly diagnosed with type 2 DM, thus possibly affecting their disease management.
Subject(s)
Depression/epidemiology , Diabetes Mellitus, Type 2/drug therapy , Drug Prescriptions/statistics & numerical data , Hypoglycemic Agents/therapeutic use , Patient Compliance , Administration, Oral , Cohort Studies , Databases, Factual , Diabetes Mellitus, Type 2/epidemiology , Female , Humans , Logistic Models , Male , Middle Aged , Retrospective Studies , West Virginia/epidemiologyABSTRACT
The objective of the study was to estimate the effect of depression on health care utilization and costs in patients newly diagnosed with type 2 diabetes. Patients were identified during a four-year enrollment period (1998-2001) from a Medicaid claims database. The final cohort consisted of 4,294 patients with type 2 diabetes (1,525 patients with depression; 2,769 patients without depression). Multivariate results indicated that significant utilization differences existed between the two groups: Patients who were depressed incurred a higher number of physician office visits, emergency room/inpatient admissions, and more prescriptions compared with patients who had diabetes but were not depressed. Patients with depression had nearly 65% higher overall health care costs than those without depression. Recognizing that depression is as a risk factor for increasing health care expenditures has the potential to improve diabetes management and related outcomes.
Subject(s)
Depression , Diabetes Mellitus, Type 2/psychology , Health Care Costs/trends , Health Services/statistics & numerical data , Adult , Cohort Studies , Female , Humans , Male , Middle Aged , Retrospective Studies , United StatesABSTRACT
Oxidative stress is a key process involved in the action of several therapeutic modalities used in cancer treatment. Ischemia reperfusion insult provides a model system for investigating the processes involved in determining the sensitivity of tumor tissue to oxidative stress. We have investigated the response of the murine CaNT tumor to ischemia reperfusion injury and the role that oxygen radicals and nitric oxide may play in this phenomenon. Our results show that little or no cell kill is detected in tumors exposed to up to 3 h of ischemia if the tumors are excised immediately before reperfusion. However, if reperfusion is permitted, then extensive cell kill is evident 24 h later. i.v. administration of superoxide dismutase or catalase, at the time when vascular reperfusion occurred, resulted in a significant protection against tumor cell kill, suggesting that the damage was mediated by oxygen radicals. Conversely, administration of an inhibitor of nitric oxide synthase, N omega-nitro-L-arginine, resulted in potentiation of tumor cell damage. Administration of a nitric oxide (NO) donor, diethylamine NO, at the time when vascular reperfusion occurred resulted in significant protection against tumor damage. These results suggest that nitric oxide is a potent mediator in determining tumor damage after ischemia reperfusion injury. The role of intrinsic NO production by murine tumors was investigated by measuring the accumulation of nitrate in the medium of tumor explants cultured in vitro in two tumors with differing sensitivity to ischemia reperfusion damage. The clamp-insensitive tumor SaS showed a greater nitrate accumulation than the clamp-sensitive tumor CaNT, which may confer a greater capacity for preventing tumor and endothelial cell damage after oxidative stress.
Subject(s)
Neoplasms, Experimental/blood supply , Nitric Oxide/physiology , Reactive Oxygen Species/metabolism , Reperfusion Injury/physiopathology , Adenocarcinoma/blood supply , Animals , Catalase/blood , Cell Survival , Female , Mice , Mice, Inbred CBA , Sarcoma, Experimental/blood supply , Superoxide Dismutase/bloodABSTRACT
The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which-by 6 h-was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N(omega)-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.
Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Neoplasms, Experimental/drug therapy , Stilbenes/pharmacology , Animals , Blood Pressure/drug effects , Male , NG-Nitroarginine Methyl Ester/pharmacology , Neoplasms, Experimental/blood supply , Phosphorylation , Rats , Regional Blood Flow/drug effects , Stilbenes/metabolism , Vascular Resistance/drug effectsABSTRACT
Metabolic reprogramming is a hallmark of cancer cells. Strap (stress-responsive activator of p300) is a novel TPR motif OB-fold protein that contributes to p53 transcriptional activation. We show here that, in addition to its established transcriptional role, Strap is localised at mitochondria where one of its key interaction partners is ATP synthase. Significantly, the interaction between Strap and ATP synthase downregulates mitochondrial ATP production. Under glucose-limiting conditions, cancer cells are sensitised by mitochondrial Strap to apoptosis, which is rescued by supplementing cells with an extracellular source of ATP. Furthermore, Strap augments the apoptotic effects of mitochondrial p53. These findings define Strap as a dual regulator of cellular reprogramming: first as a nuclear transcription cofactor and second in the direct regulation of mitochondrial respiration.
Subject(s)
Mitochondria/metabolism , Neoplasm Proteins/metabolism , Oxidative Phosphorylation , Oxygen Consumption/physiology , Tumor Suppressor Protein p53/metabolism , Apoptosis/physiology , Glucose/genetics , Glucose/metabolism , HeLa Cells , Humans , Mitochondrial Proton-Translocating ATPases , Neoplasm Proteins/genetics , RNA-Binding Proteins , Transcriptional Activation/physiology , Tumor Suppressor Protein p53/geneticsABSTRACT
This study describes a system for quantifying paclitaxel activity using the C-terminus of α-tubulin as a biomarker. Following stabilization of microtubules with paclitaxel, a specific detyrosination reaction occurs at the C-terminus of α-tubulin which could be used to assess efficacy. A fluorescence resonance energy transfer (FRET) based biosensor was synthesized comprising a short peptide that corresponded to the C-terminus of α-tubulin, a fluorophore (Abz), and a quencher (Dnp). The fluorophore added to the end of the peptide can be released upon enzymatic detyrosination. In addition, a single fluorophore-tagged peptide was also conjugated to mesoporous silica nanoparticles to examine the feasibility of combining the drug with the peptide biomarker. As a proof of concept, we found that the degree of peptide cleavage, and therefore enzymatic activity, was directly correlated with exogenous bovine carboxypeptidase (CPA) an enzyme that mimics endogenous detyrosination. In addition, we show that cell lysates obtained from paclitaxel-treated cancer cells competed with exogenous CPA for biosensor cleavage in a paclitaxel dose-dependent manner. Our work provides strong evidence for the feasibility of combining paclitaxel with a novel biosensor in a multi-load nanoparticle.
Subject(s)
Drug Monitoring/methods , Fluorescence Resonance Energy Transfer/methods , Nanocapsules/chemistry , Paclitaxel/administration & dosage , Paclitaxel/pharmacokinetics , Tubulin/pharmacokinetics , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/analysis , Antineoplastic Agents, Phytogenic/pharmacology , Biosensing Techniques/methods , Equipment Design , Equipment Failure Analysis , Nanocapsules/administration & dosage , Nanocapsules/ultrastructure , Nanoconjugates/administration & dosage , Nanoconjugates/chemistry , Nanoconjugates/ultrastructure , Paclitaxel/analysis , Particle Size , Reproducibility of Results , Sensitivity and Specificity , Silicon Dioxide/chemistry , Tubulin/analysis , Tubulin/chemistryABSTRACT
A pretargeted imaging strategy based on the HaloTag dehalogenase enzyme is described. Here, a HaloTag-Trastuzumab conjugate has been used as the primary agent targeting HER2 expression, and three new radiolabelled HaloTag ligands have been used as secondary agents, two of which offer dual-modality (SPECT/optical) imaging capability.
Subject(s)
Antibodies, Monoclonal, Humanized/metabolism , Halogens/metabolism , Hydrolases/metabolism , Optical Imaging/methods , Tomography, Emission-Computed, Single-Photon/methods , Cell Line, Tumor , Humans , Ligands , TrastuzumabABSTRACT
Superoxide anion reacts with hypochlorous acid to yield free hydroxyl radicals, as shown by the hydroxylation of benzoate. This reaction is analogous to the Haber-Weiss reaction but in the absence of metal ions is at least six orders of magnitude faster.
Subject(s)
Hydroxyl Radical/metabolism , Hypochlorous Acid/metabolism , Neutrophils/metabolism , Superoxides/metabolism , Chromatography, High Pressure Liquid , Gamma Rays , Models, ChemicalABSTRACT
The oxidative denitrification of the antitumour agent hydroxyguanidine (HOG) has been investigated by radiolysis methods and EPR spectroscopy. The azide radical (N3.), a model one-electron oxidant, reacts with HOG with the rate constant 5.1 x 10(9) dm3 mol(-1) s(-1) to yield the guanidino carbon-centred radical (HOG.) which rapidly eliminates nitric oxide (k = 3.1 x 10[3] s[-1]) with the concomitant formation of urea. The HOG. undergoes conjugation with molecular oxygen to form a peroxyl radical (HOGOO.) with a rate constant 8.8 x 10(8) dm3 mol(-1) s(-1). The HOGOO. radical also eliminates nitric oxide but may act as a precursor to the peroxynitrite (ONOO-) ion. The oxidation of HOG by the dibromide radical (Br2.-) was found to release nitric oxide with a yield of 95% relative to Br2.- as determined from the combined yields of inorganic nitrite, nitrate and a HOG/nitric oxide-adduct. This study provides a possible mechanistic basis for the oxidative denitrification of HOG which may contribute to the observed toxicity of the drug both in vitro and in vivo and for the oxidation of nonphysiological hydroxyguanidines to NO. via nitric oxide synthase-independent pathways.
Subject(s)
Antineoplastic Agents/metabolism , Guanidines/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Catalysis , Electron Spin Resonance Spectroscopy , Free Radicals , Hydroxylamines , Linear Models , Oxidation-Reduction , Peroxidase/metabolism , Pulse RadiolysisABSTRACT
Drugs based on nitroarene, aromatic N-oxide or quinone structures are frequently reduced by cellular reductases to toxic products. Reduction often involves free radicals as intermediates which react rapidly with oxygen to form superoxide radicals, inhibiting drug reduction. The elevation of cellular oxidative stress accompanying oxygen inhibition of reduction is generally less damaging than drug reduction to toxic products, so the drugs offer selective toxicity to hypoxic cells. Since such cells are resistant to radiotherapy, these bioreductive drugs offer potential in tumour therapy. The basis for the selectivity of action entails kinetic competition involving the contesting reaction pathways. The reduction potential of the drug, radical pKa and nature of radical/radical decay kinetics all influence drug activity and selectivity, including the range of oxygen tensions over which the drug offers selective toxicity. These properties may be quantified using generation of radicals by pulse radiolysis, presenting a physicochemical basis for rational drug design.
Subject(s)
Oxides/chemistry , Pharmaceutical Preparations/chemistry , Quinones/chemistry , Animals , Biotransformation , Cell Hypoxia , Drug Design , Electrons , Kinetics , Models, Chemical , Oxidation-ReductionABSTRACT
4-Hydroxyanisole is a depigmenting agent which has been shown to have activity against malignant melanoma when given intra-arterially in man. An intravenous dose escalation study has been carried out with the aim of obtaining maximum plasma concentrations in a 5 day schedule. 8 patients entered this study which was stopped because of drug toxicity after 3 patients had been treated at the third dose escalation of 15 g/m2. 2 patients had WHO grade 4 liver and one also grade 4 renal toxicity and another had grade 4 haemoglobin toxicity. Extrapolated plateau plasma levels between 112 and 860 mumol/l were obtained, which in vitro studies suggested would be cytotoxic. Hopefully, newer analogues will have a greater specificity for the melanin pathway with less toxicity.
Subject(s)
Anisoles/therapeutic use , Antineoplastic Agents/therapeutic use , Melanoma/drug therapy , Pigmentation/drug effects , Skin Neoplasms/drug therapy , Anisoles/pharmacokinetics , Antineoplastic Agents/pharmacokinetics , Drug Administration Schedule , Drug Evaluation , Evaluation Studies as Topic , Humans , Infusions, Intravenous , Lymphatic Metastasis , Melanoma/blood , Skin Neoplasms/bloodABSTRACT
Pharmacokinetic studies were carried out in mice after co-administration of 2-nitroimidazoles with differing prototropic properties: Ro 03-8799, misonidazole, SR 2508, and azomycin. In addition, the distribution of sensitizers in different areas of individual tumors, as well as several normal tissues were measured after intravenous dosing of 0.5 mmol kg-1 (145-56 mg/kg). Although there appeared to be no significant pharmacokinetic interaction between sensitizers after co-administration, there was a significant difference in the distribution of sensitizers within tumors of differing type and size. In small, fast growing SaFa and large, slow growing CaRH tumors, the levels of all sensitizers was relatively constant throughout. However, large fast growing SaFa tumors demonstrated the high degree of variability in the Ro 03-8799 concentration that is seen in the clinic. This may be important in the modelling of human tumors with regard to sensitizer distribution.
Subject(s)
Neoplasms, Experimental/metabolism , Nitroimidazoles/metabolism , Radiation-Sensitizing Agents/metabolism , Animals , Etanidazole , Mice , Misonidazole/metabolism , Tissue DistributionABSTRACT
5'-Bromo-2-deoxyuridine (BUdR) is a halogenated pyrimidine analogue that is an efficient radiosensitizer through its incorporation into DNA in place of thymidine. Radiosensitization is proportional to percentage replacement and we present here a novel derivatization technique that specifically labels the thymidine and BUdR with 4-bromomethyl-7-methoxycoumarin (BrMMC) to give the highly fluorescent coumarin derivatives which are quantitated using high performance liquid chromatography (HPLC). This allows for a simple single-stage DNA hydrolysis and sensitive peak detection. Data are presented showing the incorporation with time of BUdR into the DNA of Chinese hamster V79 cells. Attention is also drawn to the care needed in the selection of enzymes required for DNA digestion.
Subject(s)
Bromodeoxyuridine/pharmacokinetics , DNA/metabolism , Radiation-Sensitizing Agents/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Cricetinae , Cricetulus , Indicators and Reagents , UmbelliferonesABSTRACT
The "extra" radiosensitization seen with GSH-reactive nitro compounds is too large to be accounted for by GSH-depletion acting independently--there must be competition. The GS-conjugate leaks out of cells slowly and is trapped at high concentrations. Its properties, such as concentration trapped and reduction potential, must be considered. Limited therapeutic exploitation of the glutathione conjugate trapping and concomitant GSH depletion may be possible if intratumor injection is permitted.
Subject(s)
Glutathione/metabolism , Nitroimidazoles/pharmacology , Radiation-Sensitizing Agents/pharmacology , Animals , Cell Line , Cricetinae , In Vitro TechniquesABSTRACT
The radiosensitizing efficiency of a novel 2-nitroimidazole (Ro 03-8799) has been compared with that of misonidazole. Each compound was assessed by constructing dose response curves for regrowth delay using a range of drug doses. The concentration of each compound was measured in tumor homogenates with high performance liquid chromatography (HPLC). When compared on the basis of administered dose the new compound was no more efficient than misonidazole. Comparison on the basis of measured tumor concentrations showed that Ro 03-8799 was 3--4 times more efficient than misonidazole, but only at very high drug levels. Previous in vitro studies had shown a constant 10-fold difference in potency. In order to eliminate possible artifacts caused by the short half life in mice, repeated injections of Ro 03-8799 were used to maintain a constant tumor concentration for two hours before irradiation. No increase in effectiveness was observed with prolonged exposure. This is a charged compound whose distribution is pH dependent; gross tumor levels should therefore be interpreted with caution.
Subject(s)
Nitroimidazoles/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Animals , Cells, Cultured , Drug Evaluation, Preclinical , Injections, Intravenous , Mice , Misonidazole/pharmacology , Sarcoma, Experimental/radiotherapy , Time FactorsABSTRACT
The effect of hypoxic cell radiosensitizers is increased when mammalian cells are depleted of endogenous glutathione by buthionine sulphoximine pre-treatment in vitro; a similar gain has not been observed in tumors in vivo despite evidence of glutathione depletion in vivo following buthionine sulphoximine treatment. However, concentrations of biological reducing agents other than glutathione were not measured in the in vivo experiments. Other reducing agents found in tumors include alpha-tocopherol, which reduces the sensitizing efficiency of nitro-aromatic sensitizers in thiol-depleted mammalian cells. These data suggest that the failure to observe large gains in misonidazole sensitizing efficiency in thiol-depleted tumors in vivo may be due, in part, to the presence of biological reducing agents such as alpha-tocopherol.
Subject(s)
Glutathione/physiology , Radiation-Sensitizing Agents/pharmacology , Vitamin E/analogs & derivatives , Vitamin E/pharmacology , Animals , Buthionine Sulfoximine , Cell Line , Cell Survival/drug effects , Cell Survival/radiation effects , Cricetinae , Methionine Sulfoximine/analogs & derivatives , Methionine Sulfoximine/pharmacology , Radiation Tolerance/drug effectsABSTRACT
Chinese hamster V79 cells in Eagle's minimum essential medium in vitro at room temperature were incubated with the aminothiol, WR-1065, or glutathione (GSH) at extracellular concentrations of approximately 1 mmol dm-3. Average intracellular concentrations of GSH, cysteine, and WR-1065 were measured by high performance liquid chromatography, and the effective reducing environment near DNA probed by staining the cells with acridine orange (AO) and measuring the delayed fluorescence. Exposure to either thiol resulted in a rapid, 10-fold increase in average intracellular cysteine concentrations (to about 1 mmol dm-3). Adding extracellular GSH after prior depletion of GSH by treatment with L-buthionine sulfoximine (BSO) did not restore intracellular GSH, but intracellular cysteine was elevated 10-fold. These results are ascribed to thiol/disulfide exchange with cystine in the medium. WR-1065 slowly concentrated intracellularly to approximately 160% of the extracellular concentration. Chemical conjugation of GSH in cells decreased the reducing environment near DNA, but BSO treatment altered the uptake of AO. The electrostatic attraction of WR-1065 toward isolated DNA was markedly affected by ionic strength.
Subject(s)
Glutathione/pharmacokinetics , Mercaptoethylamines/pharmacokinetics , Radiation-Protective Agents/pharmacokinetics , Animals , Cell Line , Chromatography, High Pressure Liquid , Cricetinae , Cysteine/analysis , Extracellular Space/metabolism , In Vitro Techniques , Intracellular Fluid/metabolism , Subcellular Fractions/metabolismABSTRACT
A prospective randomized trial is reported involving 97 patients with locally advanced cancer of the head and neck. Using six large fractions of radiation (3600 rad in 17 days) the addition of misonidazole (2.0gm per m2 body surface) with each fraction did not increase the local control rate at one year. It is thought that this is probably because of an inadequate tumor concentration of the drug.